FIG 9.

In vivo effect of mutant virus in the mouse model of biliary atresia. (A) Symptoms were recorded for different groups of mice for 16 days. One hundred percent of the mice in the RRV (n = 21)- and RRV^VP4-XbaI (n = 22)-treated groups showed symptoms, but only 80% of those in the RRV^VP4-R446G-injected group (n = 23) showed symptoms, and this gradually decreased to 40% later. (B) Survival was noted to be significantly improved (85%) for mice injected with RRV^VP4-R446G compared to that for mice injected with RRV (0%) or RRV^VP4-XbaI (10%). *, P < 0.05.